These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 21988293)
1. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293 [TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Paediatr Drugs; 2012 Dec; 14(6):429-33. PubMed ID: 23013458 [TBL] [Abstract][Full Text] [Related]
3. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Plosker GL Pharmacoeconomics; 2011 May; 29(5):439-54. PubMed ID: 21504245 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries. Plosker GL Drugs R D; 2012 Dec; 12(4):239-44. PubMed ID: 23017130 [TBL] [Abstract][Full Text] [Related]
5. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. McCormack PL; Keam SJ Paediatr Drugs; 2009; 11(1):75-88. PubMed ID: 19127963 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Standaert B; Parez N; Tehard B; Colin X; Detournay B Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820 [TBL] [Abstract][Full Text] [Related]
8. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. Rose J; Hawthorn RL; Watts B; Singer ME BMJ; 2009 Sep; 339():b3653. PubMed ID: 19783581 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Patel HD; Roberts ET; Constenla DO Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497 [TBL] [Abstract][Full Text] [Related]
10. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation. Fisman DN; Chan CH; Lowcock E; Naus M; Lee V Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595 [TBL] [Abstract][Full Text] [Related]
12. A rotavirus vaccine for infants: the Asian experience. Phua KB; Emmanuel SC; Goh P; Quak SH; Lee BW; Han HH; Ward RL; Bernstein DI; De Vos B; Bock HL Ann Acad Med Singap; 2006 Jan; 35(1):38-44. PubMed ID: 16470273 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252 [TBL] [Abstract][Full Text] [Related]
14. Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies. Hungerford D; Smith K; Tucker A; Iturriza-Gómara M; Vivancos R; McLeonard C; A Cunliffe N; French N BMC Infect Dis; 2017 Aug; 17(1):569. PubMed ID: 28810833 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of childhood rotavirus vaccination in Germany. Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. Muhsen K; Anis E; Rubinstein U; Kassem E; Goren S; Shulman LM; Ephros M; Cohen D Clin Microbiol Infect; 2018 Jan; 24(1):53-59. PubMed ID: 28442435 [TBL] [Abstract][Full Text] [Related]
17. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Goossens LM; Standaert B; Hartwig N; Hövels AM; Al MJ Vaccine; 2008 Feb; 26(8):1118-27. PubMed ID: 18215445 [TBL] [Abstract][Full Text] [Related]
18. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects. Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065 [TBL] [Abstract][Full Text] [Related]
19. Global economic evaluations of rotavirus vaccines: A systematic review. Kotirum S; Vutipongsatorn N; Kongpakwattana K; Hutubessy R; Chaiyakunapruk N Vaccine; 2017 Jun; 35(26):3364-3386. PubMed ID: 28504193 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ; Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]